Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC

Nature Reviews Urology

Volumn 8, Issue 3, 2011, Pages 165-171

  Yamasaki, Toshinari ^a   Tran, Tram Anh T ^a   Oz, Orhan K ^a   Raj, Ganesh V ^a   Schwarz, Roderich E ^a   DeBerardinis, Ralph J ^a   Zhang, Xuewu ^a   Brugarolas, James ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18; FUMARATE HYDRATASE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; SUNITINIB; TEMSIROLIMUS;

ADULT; ARTERIOGRAPHY; ARTICLE; CANCER SURGERY; CASE REPORT; CITRIC ACID CYCLE; COLON RESECTION; COMPUTER ASSISTED TOMOGRAPHY; DNA SEQUENCE; DRUG BLOOD LEVEL; DRUG HALF LIFE; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; GENE MUTATION; GENETIC SCREENING; GERM LINE; HETEROZYGOSITY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY ARTERY EMBOLIZATION; KIDNEY BIOPSY; KIDNEY CARCINOMA; LAPAROTOMY; LEIOMYOMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS RESECTION; PAPILLARY CARCINOMA; PAPILLARY RENAL CELL CARCINOMA TYPE 2; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SPLENECTOMY; TOTAL PARENTERAL NUTRITION; TUMOR CELL; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; FATAL OUTCOME; FEMALE; FUMARATE HYDRATASE; GLYCOLYSIS; HUMANS; KIDNEY NEOPLASMS; PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952708088     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2010.234     Document Type: Article

References (30)

1. Hudes, G. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2281 (2007).
2. Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449-456 (2008).
3. Tomlinson, I. P. et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat. Genet. 30, 406-410 (2002).
4. Toro, J. R. et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am. J. Hum. Genet. 73, 95-106 (2003).
5. Gottlieb, E. & Tomlinson, I. P. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat. Rev. Cancer 5, 857-866 (2005).
6. Lehtonen, H. J. et al. Increased risk of cancer in patients with fumarate hydratase germline mutation. J. Med. Genet. 43, 523-526 (2006).
7. rd et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J. Urol. 177, 2074-2079 (2007).
8. Bayley, J. P., Launonen, V. & Tomlinson, I. P. The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency. BMC Med. Genet. 9, 20 (2008).
9. Weaver, T. M., Levitt, D. G., Donnelly, M. I., Stevens, P. P. & Banaszak, L. J. The multisubunit active site of fumarase C from Escherichia coli. Nat. Struct. Biol. 2, 654-662 (1995).
10. Isaacs, J. S. et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8, 143-153 (2005).
11. -) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genet. Cytogenet. 196, 45-55 (2010).
12. O'Flaherty, L. et al. Dysregulation of hypoxia pathways in fumarate hydratase-deficient cells is independent of defective mitochondrial metabolism. Hum. Mol. Genet. 19, 3844-3851 (2010).
13. Kiuru, M. et al. Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. Cancer Res. 62, 4554-4557 (2002).
14. Morris, M. R. et al. Molecular genetic analysis of FIH-1, FH, and SDHB candidate tumour suppressor genes in renal cell carcinoma. J. Clin. Pathol. 57, 706-711 (2004).
15. Sudarshan, S., Pinto, P. A., Neckers, L. & Linehan, W. M. Mechanisms of disease: hereditary leiomyomatosis and renal cell cancer - a distinct form of hereditary kidney cancer. Nat. Clin. Pract. Urol. 4, 104-110 (2007).
16. Choueiri, T. K. et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J. Clin. Oncol. 26, 127-131 (2008).
17. Plimack, E. R. et al. Sunitinib in papillary renal cell carcinoma (pRCC): results from a single-arm phase II study. J. Clin. Oncol. 28, 4604 (2010).
18. Pollard, P. J. et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations. Hum. Mol. Genet. 14, 2231-2239 (2005).
19. Sudarshan, S. et al. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1α stabilization by glucose-dependent generation of reactive oxygen species. Mol. Cell Biol. 29, 4080-4090 (2009).
20. Pelicano, H., Martin, D. S., Xu, R. H. & Huang, P. Glycolysis inhibition for anticancer treatment. Oncogene 25, 4633-4646 (2006).
21. Stein, M. et al. Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate 70, 1388-1394 (2010).
22. Raez, L. E. et al. Responses to the combination of the glycolytic inhibitor 2-deoxy-glucose (2DG) and docetaxel (DC) in patients with lung and head and neck (H/N) carcinomas. J. Clin. Oncol. 25, 14025 (2007).
23. Alam, N. A. et al. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. Hum. Mol. Genet. 12, 1241-1252 (2003).
24. Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123-134 (2009).
25. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005).
26. Linehan, W. M. et al. Hereditary kidney cancer: unique opportunity for disease-based therapy. Cancer 115, 2252-2261 (2009).
27. Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033 (2009).
28. Mankoff, D. A. et al. Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond. Clin. Cancer Res. 13, 3460-3469 (2007).
29. Inoki, K., Zhu, T. & Guan, K. L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115, 577-590 (2003).
30. Kimura, N. et al. A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway. Genes Cells 8, 65-79 (2003).